Baseline adiponectin levels do not influence the response to pioglitazone in act now

Diabetes Care

Volumn 37, Issue 6, 2014, Pages 1706-1711

  Tripathy, Devjit ^a   Clement, Stephen C ^b   Schwenke, Dawn C ^c,d   Banerji, MaryAnn ^e   Bray, George A ^f   Buchanan, Thomas A ^g   Gastaldelli, Amalia ^a   Henry, Robert R ^h   Kitabchi, Abbas E ⁱ   Mudaliar, Sunder ^h   Ratner, Robert E ^j   Stentz, Frankie B ⁱ   Musi, Nicolas ^a   Reaven, Peter D ^c   De Fronzo, Ralph A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c CARL T HAYDEN VA MEDICAL CENTER   (United States)

^d ARIZONA STATE UNIVERSITY   (United States)

^e SUNY DOWNSTATE MEDICAL CENTER   (United States)

^f PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^j MEDSTAR RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; INSULIN; PIOGLITAZONE; PLACEBO; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PROTEIN BLOOD LEVEL; ANALYSIS; BLOOD; COHORT ANALYSIS; DIABETES MELLITUS, TYPE 2; DISEASE COURSE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADIPONECTIN; BLOOD GLUCOSE; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 84901435190     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-1745     Document Type: Article

References (22)

1. Bullard KM, Saydah SH, Imperatore G, et al. Secular changes in U.S. Prediabetes prevalence defined by hemoglobin A1c and fasting plasma glucose: National Health and Nutrition Examination Surveys, 1999-2010. Diabetes Care 2013; 36:2286-2293
2. Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia 2012;55:2319-2326
3. Yamamoto Y, Hirose H, Saito I, et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond) 2002;103:137-142
4. Civitarese AE, Ukropcova B, Carling S, et al. Role of adiponectin in human skeletal muscle bioenergetics. Cell Metab 2006;4:75-87
5. Kriketos AD, Gan SK, Poynten AM, Furler SM, Chisholm DJ, Campbell LV. Exercise increases adiponectin levels and insulin sensitivity in humans.diabetes Care 2004;27:629-630
6. Tonelli J, Li W, Kishore P, et al. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 2004;53: 1621-1629
7. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003;423:762-769
8. Iwabu M, Yamauchi T, Okada-Iwabu M, et al. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature 2010;464:1313-1319
9. Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002; 277:25863-25866
10. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002;8:731-737
11. Mather KJ, Funahashi T, Matsuzawa Y, et al.; Diabetes Prevention Program. Adiponectin, change in adiponectin, and progression todiabetes in the Diabetes Prevention Program.diabetes 2008;57:980-986
12. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004;89:4312-4319
13. BajajM, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia 2007;50:1723-1731
14. DeFronzo RA, Tripathy D, Schwenke DC, et al.; ACT NOWStudy. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011;364:1104-1115
15. Beard JC, Bergman RN, Ward WK, Porte D Jr. The insulin sensitivity index in nondiabetic man. Correlation between clamp-derived and IVGTT-derived values. Diabetes 1986;35:362-369 (Pubitemid 16137009
16. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
17. Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50: 2094-2099
18. Rasouli N, Yao-Borengasser A, Miles LM, Elbein SC, Kern PA. Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. Am J Physiol Endocrinol Metab 2006;290:E42-E46
19. Banga A, Unal R, Tripathi P, et al. Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids. Am J Physiol Endocrinol Metab 2009;296:E480-E489
20. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus.diabetes 2009;58:773-795
21. Tomas E, Tsao TS, Saha AK, et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci U S A 2002;99: 16309-16313
22. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMPactivated protein kinase. Nat Med 2002;8: 1288-1295